Welcome to our dedicated page for Beyond Air news (Ticker: XAIR), a resource for investors and traders seeking the latest updates and insights on Beyond Air stock.
Beyond Air, Inc. (NASDAQ: XAIR) is a commercial-stage medical device and biopharmaceutical company centered on nitric oxide (NO) technologies, and its news flow reflects both commercial execution and clinical development. Company announcements frequently highlight progress with the LungFit PH system, a cylinder-free NO generator and delivery device approved for treating term and near-term neonates with hypoxic respiratory failure associated with pulmonary hypertension. Investors can follow updates on U.S. hospital adoption, international distribution agreements, regulatory milestones, and quality certifications related to this platform.
News items also cover Beyond Air’s broader LungFit pipeline, including clinical trials evaluating higher-concentration NO for severe lung infections such as viral community-acquired pneumonia and nontuberculous mycobacteria. These stories often discuss regulatory submissions, design patents for next-generation devices, and participation in medical and industry conferences.
On the biopharmaceutical side, Beyond Air and its affiliates generate news about oncology and neurology programs. Beyond Cancer, Ltd. reports early-stage clinical data and preclinical work using ultra-high concentration NO for solid tumors, while NeuroNOS communications describe small-molecule nNOS inhibitors, preclinical findings in Autism Spectrum Disorder and brain cancers, and U.S. FDA Orphan Drug Designations for glioblastoma and Phelan-McDermid Syndrome. Transactions such as the agreement for XTL Biopharmaceuticals to acquire a majority stake in NeuroNOS are also covered.
Capital markets and corporate governance updates are another recurring theme, including private placements, warrant exercises, promissory notes, equity purchase agreements, reverse stock splits, and leadership changes. For investors and analysts tracking XAIR, this news page provides a centralized view of commercial rollouts, clinical milestones, financing activity, and strategic partnerships that shape the company’s nitric oxide-focused portfolio.
NeuroNOS, a subsidiary of Beyond Air (NASDAQ: XAIR), has received FDA Orphan Drug Designation (ODD) for its lead therapy BA-101 in treating Glioblastoma (GBM), an aggressive brain cancer. This marks the company's second ODD and its entry into oncology.
GBM currently has limited treatment options with median survival less than 12 months, and survival rates of less than 20% at two years and less than 10% at five years. The ODD grants several benefits, including seven years of market exclusivity, tax credits for clinical trials, and prescription drug user fee waivers.
The company's approach focuses on NO inhibition strategy, supported by research showing nitric oxide as an important modulator in GBM treatment response.
Beyond Air (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company specializing in nitric oxide (NO) treatments, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York.
Chairman and CEO Steve Lisi will represent the company, with an on-demand presentation webcast available starting September 5, 2025, at 7:00 a.m. ET. Management will also be available for one-on-one investor meetings during the conference.
Beyond Air (NASDAQ: XAIR) has expanded its global distribution network for LungFit PH, a medical device that generates nitric oxide from ambient air. The company has signed new distribution agreements in Japan, South Korea, Costa Rica, Guatemala, Panama, and El Salvador, bringing its total international coverage to 34 countries with a combined population of 2.7 billion people.
In Japan, Beyond Air partnered with AMCO Incorporated, a leading medical device distributor with over 70 years of experience. The LungFit PH system eliminates the need for traditional high-pressure cylinders, offering a more efficient and environmentally friendly solution for hospital settings. Hospital tender submissions are currently in progress in several regions while awaiting regulatory approvals in others.
Beyond Air (NASDAQ: XAIR) reported strong fiscal Q1 2026 results, with revenue surging 157% to $1.8 million compared to $0.7 million in the same period last year. The company secured a significant national group purchasing agreement with Premier, Inc., gaining access to over 4,350 member hospitals and health systems.
The company reaffirmed its FY2026 revenue guidance of $12-16 million. LungFit PH's commercial expansion continues globally, now reaching over 30 countries. Beyond Air reported a net loss of $7.7 million ($1.53 per share) and cash position of $6.5 million as of June 30, 2025. The company recently completed a 1-for-20 reverse stock split to maintain Nasdaq compliance.
Beyond Air (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company specializing in nitric oxide (NO) treatments, has scheduled its first fiscal quarter 2026 financial results conference call for Tuesday, August 12, 2025, at 4:30 PM ET.
The company will discuss its financial performance for the quarter ended June 30, 2025. Investors can access the conference call through domestic (1-877-407-0784) or international (1-201-689-8560) dial-in numbers using conference ID 13754769. A webcast will be available through the company's website, with a replay accessible after the call.
Beyond Air (NASDAQ: XAIR) has secured a national group purchasing agreement with Premier, Inc., effective July 15th, 2025. The agreement enables Premier's network of healthcare providers to access special pricing for Beyond Air's LungFit PH system and disposable NO2 Smart Filters.
The LungFit PH platform utilizes patented Ionizer™ technology to generate unlimited, on-demand nitric oxide from ambient air for ventilator delivery. The system operates on minimal power, equivalent to a 60-watt lightbulb, and includes Smart Filters that provide 12 hours of uninterrupted therapy. Premier serves two-thirds of U.S. healthcare providers, making this agreement significant for Beyond Air's market reach.
Beyond Air (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company specializing in nitric oxide (NO) treatments, has announced its upcoming fiscal year 2025 financial results conference call. The company will report its fiscal fourth quarter and full year results ended March 31, 2025 on Tuesday, June 17, 2025.
The management team will host a conference call and webcast at 4:30 PM Eastern Time. Investors can access the call through domestic (1-877-407-0784) or international (1-201-689-8560) lines using conference ID 13753945. A webcast will be available through the company's website, with a replay accessible one hour after the call.
Beyond Air (NASDAQ: XAIR) has secured U.S. Patent No. 12,274,830 from the USPTO for its method of treating non-tuberculous mycobacteria (NTM) lung infections using gaseous nitric oxide (gNO). The patent covers a specific dosing regimen of 200-320 ppm gNO for 10-45 minutes, 2-5 times daily, delivering 300-900 ppm-hrs of gNO per day over at least 14 days. The patent protection extends until March 12, 2038.
The company recently reported positive clinical data in the American Thoracic Society Journal demonstrating LungFit GO's potential for safe and effective at-home treatment of NTM infections. NTM is a rare but serious bacterial lung infection affecting approximately 13% of U.S. cystic fibrosis patients as of 2017. Current treatments involve lengthy antibiotic combinations with poor efficacy and potential severe side effects.
FAQ
What is the current stock price of Beyond Air (XAIR)?
What is the market cap of Beyond Air (XAIR)?
